Establishment Labs : Third Quarter 2022 Results

2022Q3

EARNINGS

"The significant momentum in our business continued in the third quarter of 2022 and we expect our strong financial results will

continue into the fourth quarter and into 2023," said Juan José Chacón-Quirós, Founder and Chief Executive Officer.

"We are preparing for a number of significant new opportunities, including launches of Motiva into the U.S. and China and the commercial introduction of Mia FemtechTM. In October, we hosted a webcast highlighting the progress we have made in bringing Mia® to market and we remain on track for commercialization in the first half of 2023. We have also completed all surgeries in our U.S. IDE clinical trial, and we expect to submit the fourth and final module for our first PMA approval before the end of the year."

FINANCIAL HIGHLIGHTS

for the third quarter ended September 30, 2022

REVENUE	IN DETAIL
$38.2	68.1% Gross Profit
MILLION	$36.6millon Operating Expenses
	$65.3millon Cash Balance
	31.7%
	YoY Growth

UPDATED 2022 REVENUE GUIDANCEGLOBAL SALES

$162	25% to 28%	33%	23%	44%
$158 to	annual growth over 2021
MILLION	30% to 33%
	annual growth, excluding	Latin America	Europe	Asia Pacific &
	currency changes, over 2021

Middle East

Direct Sales 38% | Distributors 62%

RECENT BUSINESS HIGHLIGHTS

• Mia FemtechTM Day Oct 5, 2022.
• Pink is for Power:
• • 30+ global events to promote Breast Cancer Awareness Month, including awareness and education campaigns, program sponsorships, and partnerships.
  • Breast Reconstruction partnership program in Brazil, targeting more than 300 women to receive breast reconstruction surgery.
• Establishment Labs attended the PSTM2022 conference in Boston and hosted a surgeon symposium with Dr. Robert Langer from MIT.
• VII World Symposium on Ergonomic Implants (WSEI), first time in Thailand.

WHAT'S COMING

Mia FemtechTM commercialization	China approval and launch expected in	Expect to submit Motiva® Implants for
expected in 1H 2023	1H 2023	U.S. FDA approval in Q4 2022

Motiva® Implants are currently not approved for commercial distribution in the United States and are undergoing clinical investigation pursuant to USFDA regulations for investigational medical devices.

Please refer to theEstablishment Labs Reports Third Quarter 2022 Financial Resultspress release for official information on third quarter 2022 financial results.